Bruce Japsen

Bruce Japsen is a financial and healthcare reporter with a focus on business decisions and financial results within the industry. He has been covering the healthcare sector for several years, providing insightful analysis on various companies' performance and market trends. His articles often cover topics such as pharmacy services, health-care transformation, and investment decisions in the industry. Japsen's reporting is known for its neutral tone and accurate information that helps readers understand complex financial situations.

Biography:  https://www.forbes.com/sites/brucejapsen/

81%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

90%

Examples:

  • The author has a background in reporting on financial results and business decisions within the healthcare industry.
  • There are instances where the author reports on companies' financial losses without any negative language or tone, indicating a neutral approach to reporting.

Conflicts of Interest

50%

Examples:

  • In one article, it is mentioned that VillageMD operates standalone doctor practices and physician-staffed clinics attached to Walgreens. The author does not disclose any personal or financial connections to the company.

Contradictions

85%

Examples:

  • In one article, it is mentioned that Walgreens reported fiscal second-quarter sales that beat Wall Street's expectations while in another article it is stated that the company lowered the high end of its full-year adjusted earnings outlook in part due to a challenging retail environment in the U.S.
  • There are instances where the author reports on companies' financial losses without any negative language or tone, indicating a neutral approach to reporting.

Deceptions

100%

Examples:

  • There are no instances of deceptive practices in the articles provided.

Recent Articles

Walgreens Expands Specialty Pharmacy Business with Focus on Gene and Cell Therapies: New Facility, 1,500 Specialty-Trained Pharmacists, and $24 Billion Market

Walgreens Expands Specialty Pharmacy Business with Focus on Gene and Cell Therapies: New Facility, 1,500 Specialty-Trained Pharmacists, and $24 Billion Market

Broke On: Thursday, 25 April 2024 Walgreens launches Walgreens Specialty Pharmacy, a $24 billion business focusing on gene and cell therapies, integrating new services with existing assets. The expansion includes an 18,000-sqft facility in Pittsburgh to manage complex supply chains for high-cost treatments like cancer and HIV. With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy team members, Walgreens Specialty Pharmacy aims to improve financial performance through expanded offerings in the specialty pharmacy market.
Walgreens Boots Alliance reports $6 billion net loss in Q2 due to VillageMD decline

Walgreens Boots Alliance reports $6 billion net loss in Q2 due to VillageMD decline

Broke On: Thursday, 28 March 2024 Walgreens Boots Alliance, Inc. reported a steep net loss for the fiscal second quarter of 2024 due to a $6 billion charge related to its investment in VillageMD's decline in value. Despite closing dozens of clinics and financial struggles, Walgreens sees VillageMD as critical to its transformation from drugstore chain into health care company. Meanwhile, Walgreens U.S retail pharmacy segment generated strong sales with an almost 5% increase from the same period last year.